Annual Cash & Cash Equivalents
$59.41 M
-$13.23 M-18.22%
December 31, 2023
Summary
- As of February 7, 2025, IMRX annual cash & cash equivalents is $59.41 million, with the most recent change of -$13.23 million (-18.22%) on December 31, 2023.
- During the last 3 years, IMRX annual cash & cash equivalents has risen by +$22.32 million (+60.17%).
- IMRX annual cash & cash equivalents is now -20.67% below its all-time high of $74.89 million, reached on December 31, 2021.
Performance
IMRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$45.21 M
-$14.52 M-24.31%
September 30, 2024
Summary
- As of February 7, 2025, IMRX quarterly cash and cash equivalents is $45.21 million, with the most recent change of -$14.52 million (-24.31%) on September 30, 2024.
- Over the past year, IMRX quarterly cash and cash equivalents has dropped by -$21.08 million (-31.80%).
- IMRX quarterly cash and cash equivalents is now -57.72% below its all-time high of $106.93 million, reached on September 30, 2021.
Performance
IMRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
IMRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.2% | -31.8% |
| 3 y3 years | +60.2% | -37.8% |
| 5 y5 years | +331.0% | -37.8% |
IMRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -20.7% | at low | -56.5% | at low |
| 5 y | 5-year | -20.7% | +331.0% | -57.7% | +46.1% |
| alltime | all time | -20.7% | +331.0% | -57.7% | +46.1% |
Immuneering Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $45.21 M(-24.3%) |
| Jun 2024 | - | $59.73 M(-9.9%) |
| Mar 2024 | - | $66.29 M(+11.6%) |
| Dec 2023 | $59.41 M(-18.2%) | $59.41 M(-12.7%) |
| Sep 2023 | - | $68.04 M(-34.6%) |
| Jun 2023 | - | $104.02 M(+34.3%) |
| Mar 2023 | - | $77.43 M(+6.6%) |
| Dec 2022 | $72.64 M | $72.64 M(-4.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $76.42 M(-13.1%) |
| Jun 2022 | - | $87.94 M(+16.9%) |
| Mar 2022 | - | $75.21 M(+0.4%) |
| Dec 2021 | $74.89 M(+101.9%) | $74.89 M(-30.0%) |
| Sep 2021 | - | $106.93 M(+112.8%) |
| Jun 2021 | - | $50.25 M(+62.4%) |
| Mar 2021 | - | $30.93 M(-16.6%) |
| Dec 2020 | $37.09 M(+169.1%) | $37.09 M |
| Dec 2019 | $13.78 M | - |
FAQ
- What is Immuneering annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Immuneering?
- What is Immuneering annual cash & cash equivalents year-on-year change?
- What is Immuneering quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Immuneering?
- What is Immuneering quarterly cash and cash equivalents year-on-year change?
What is Immuneering annual cash & cash equivalents?
The current annual cash & cash equivalents of IMRX is $59.41 M
What is the all time high annual cash & cash equivalents for Immuneering?
Immuneering all-time high annual cash & cash equivalents is $74.89 M
What is Immuneering annual cash & cash equivalents year-on-year change?
Over the past year, IMRX annual cash & cash equivalents has changed by -$13.23 M (-18.22%)
What is Immuneering quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IMRX is $45.21 M
What is the all time high quarterly cash and cash equivalents for Immuneering?
Immuneering all-time high quarterly cash and cash equivalents is $106.93 M
What is Immuneering quarterly cash and cash equivalents year-on-year change?
Over the past year, IMRX quarterly cash and cash equivalents has changed by -$21.08 M (-31.80%)